Dinghu Zhang1,2, Yanhong Chu1, Hanqing Qian1, Lingyu Qian1, Jie Shao1, Qiuping Xu1, Lixia Yu1, Rutian Li1, Quanan Zhang3, Fenglei Wu4, Baorui Liu1, Qin Liu1. 1. The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China. 2. Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, People's Republic of China. 3. Department of Oncology, Jiangning Hospital, Nanjing, People's Republic of China. 4. Department of Oncology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, People's Republic of China.
Abstract
INTRODUCTION: Gambogic acid (GA) is proved to have anti-tumor effects on gastric cancer. Due to poor solubility, non-specific biological distribution, toxicity to normal tissues and short half-life, it is hard to be applied into the clinic. To overcome these issues, we developed a thermosensitive and injectable hydrogel composed of hydroxypropyl cellulose, silk fibroin and glycerol, with short gelling time, good compatibility and sustained release, and demonstrated that the hydrogel packaged with gambogic acid nanoparticles (GA-NPs) and tumor-penetrating peptide iRGD could improve the anti-tumor activity. METHODS: The Gelling time and micropore size of the hydrogels were regulated through different concentrations of glycerol. Controlled release characteristics of the hydrogels were evaluated with a real-time near-infrared fluorescence imaging system. Location of nanoparticles from different carriers was traced by confocal laser scanning microscopy. The in vivo antitumor activity of the hydrogels packaging GA-NPs and iRGD was evaluated by investigating tumor volume and tumor size. RESULTS: The thermo-sensitive properties of hydrogels were characterized by 3-4 min, 37°C, when glycerol concentration was 20%. The hydrogels physically packaged with GA-NPs and iRGD showed higher fluorescence intensity than other groups. The in vivo study indicated that the co-administration of GA-NPs and iRGD by hydrogels had higher antitumor activity than the GA-loaded hydrogels and free GA combining with iRGD. Free GA group showed few antitumor effects. Compared with the control group, the body weight in other groups had no obvious change, and the count of leukocytes and hemoglobin was slightly decreased. DISCUSSION: The hydrogel constructed iRGD and GA-NPs exerted an effective anti-tumor effect possibly due to retention effect, local administration and continuous sustained release of iRGD promoting the penetration of nanoparticles into a deep part of tumors. The delivery system showed little systemic toxicity and would provide a promising strategy to improve anti-gastric cancer efficacy.
INTRODUCTION: Gambogic acid (GA) is proved to have anti-tumor effects on gastric cancer. Due to poor solubility, non-specific biological distribution, toxicity to normal tissues and short half-life, it is hard to be applied into the clinic. To overcome these issues, we developed a thermosensitive and injectable hydrogel composed of hydroxypropyl cellulose, silk fibroin and glycerol, with short gelling time, good compatibility and sustained release, and demonstrated that the hydrogel packaged with gambogic acid nanoparticles (GA-NPs) and tumor-penetrating peptide iRGD could improve the anti-tumor activity. METHODS: The Gelling time and micropore size of the hydrogels were regulated through different concentrations of glycerol. Controlled release characteristics of the hydrogels were evaluated with a real-time near-infrared fluorescence imaging system. Location of nanoparticles from different carriers was traced by confocal laser scanning microscopy. The in vivo antitumor activity of the hydrogels packaging GA-NPs and iRGD was evaluated by investigating tumor volume and tumor size. RESULTS: The thermo-sensitive properties of hydrogels were characterized by 3-4 min, 37°C, when glycerol concentration was 20%. The hydrogels physically packaged with GA-NPs and iRGD showed higher fluorescence intensity than other groups. The in vivo study indicated that the co-administration of GA-NPs and iRGD by hydrogels had higher antitumor activity than the GA-loaded hydrogels and free GA combining with iRGD. Free GA group showed few antitumor effects. Compared with the control group, the body weight in other groups had no obvious change, and the count of leukocytes and hemoglobin was slightly decreased. DISCUSSION: The hydrogel constructed iRGD and GA-NPs exerted an effective anti-tumor effect possibly due to retention effect, local administration and continuous sustained release of iRGD promoting the penetration of nanoparticles into a deep part of tumors. The delivery system showed little systemic toxicity and would provide a promising strategy to improve anti-gastric cancer efficacy.
Authors: Paul Z Elias; Gary W Liu; Hua Wei; Michael C Jensen; Philip J Horner; Suzie H Pun Journal: J Control Release Date: 2015-03-04 Impact factor: 9.776
Authors: Kazuki N Sugahara; Pablo Scodeller; Gary B Braun; Tatiana Hurtado de Mendoza; Chisato M Yamazaki; Michael D Kluger; Joji Kitayama; Edwin Alvarez; Stephen B Howell; Tambet Teesalu; Erkki Ruoslahti; Andrew M Lowy Journal: J Control Release Date: 2015-06-11 Impact factor: 9.776
Authors: D Alves Cardoso; J J J P van den Beucken; L L H Both; J Bender; J A Jansen; S C G Leeuwenburgh Journal: J Biomed Mater Res A Date: 2013-06-12 Impact factor: 4.396
Authors: Y Akashi; T Oda; Y Ohara; R Miyamoto; T Kurokawa; S Hashimoto; T Enomoto; K Yamada; M Satake; N Ohkohchi Journal: Br J Cancer Date: 2014-02-20 Impact factor: 7.640
Authors: Kasiemobi E Pulliam; Bernadin Joseph; Amy T Makley; Charles C Caldwell; Alex B Lentsch; Michael D Goodman; Timothy A Pritts Journal: Surgery Date: 2021-12-30 Impact factor: 3.982